Kesimpta® ofatumumab

Scan or click (if viewing digitally) the QR code to view the Prescribing Information

Initiating treatment with KESIMPTA® (ofatumumab)

KESIMPTA is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis with active disease defined by clinical or imaging features.[1]
KESIMPTA is intended for patient self-administration by subcutaneous injection following initial HCP guidance.
For further information regarding KESIMPTA, please refer to the SmPC.

BEFORE PRESCRIBING KESIMPTA

Checks related to KESIMPTA contraindications[1]

- Check patient is not hypersensitive to the active substance, or any excipients ☐
- Check whether the patient takes immuno-suppressants or is severely immunocompromised ☐
- Check for severe action infection (including progressive multifocal leukoencephalopathy [PML]). If the patient has an active infection, administration should be delayed until the infection is resolved (KESIMPTA must not be given to patients in a severely immunocompromised state until it resolves [e.g. significant neutropenia or lymphopenia]). ☐
- Ensure patient does not have active malignancy ☐

Other checks

- Perform hepatitis B virus (HBV) screening ☐
- Check patient's immune status ☐

Local KESIMPTA prescribing requirements

Add in your local requirements in the free spaces as appropriate

- ..... ☐
- ..... ☐
- ..... ☐
- ..... ☐
- ..... ☐

Scan or click (if viewing digitally) the QR code for information on KESIMPTA's safety profile.

PRE-INITIATION

Prescribing considerations and precautions in the KESIMPTA SmPC (please refer to the SmPC for more information)[1]

- Check for any recent and/or upcoming vaccinations; check patient is up to date with vaccinations (vaccination with live or live-attenuated vaccines is not recommended during treatment and after discontinuation until B-cell repletion) ☐
- If relevant, check for pregnancy and discuss family planning (treatment with KESIMPTA should be avoided during pregnancy unless the potential benefit to the mother outweighs the potential risk to the foetus; women of childbearing potential should use effective contraception while receiving KESIMPTA and for 6 months after the last administration of KESIMPTA) ☐
- If HBV positive, the patient should consult a liver disease expert and should be monitored and managed following local medical standards to prevent HBV reactivation (patients with active hepatitis B disease should not be treated with KESIMPTA) ☐
- Inform the patient of the potential for injection-related reactions ☐
- Check for medical history of PML and any clinical symptoms or MRI findings that may be suggestive of PML. If PML is suspected, treatment with KESIMPTA should be suspended until PML has been excluded ☐
- Check if the patient is using other immunosuppressants as it is not recommended to use them concomitantly with KESIMPTA (except corticosteroids for symptomatic treatment of relapses) ☐

Local KESIMPTA pre-initiation requirements

Add in your local requirements in the free spaces as appropriate

- ..... ☐
- ..... ☐
- ..... ☐
- ..... ☐
- ..... ☐

NOVARTIS

Your Local Novartis KAM .....

UK | January 2025 | FA-11338736

THE FIRST DOSE

KESIMPTA is a self-administered subcutaneous injection. The first injection should be performed under the guidance of an appropriately trained healthcare professional (refer to SmPC for full injection guidance)[1]

If you are using the KesimptaConnect service, a KesimptaConnect nurse may carry out the pre-initiation checks and supervise the first injection from the patient's home. Speak to your Novartis Key Account Manager (KAM) to find out more.*

KesimptaConnect is a patient support programme organised and funded by Novartis.

Initial doses

Monthly injections at home

Start

No injection

Use of premedication is not required[1]

*KesimptaConnect consists of KesimptaConnect Homecare and KesimptaConnect Nurse services, which are provided as a package deal, and the KesimptaConnect App, which is a patient support programme (PSP).

Adverse events should be reported.
Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report or alternatively email medinfo.uk@novartis.com or call 01276 698370.

HBV, hepatitis B virus; HCP, healthcare professional; KAM, key account manager; PML, progressive multifocal leukoencephalopathy; PSP, patient support programme; SmPC, summary of product characteristics.

Reference

1. KESIMPTA (ofatumumab) Summary of Product Characteristics.

NOVARTIS

UK | January 2025 | FA-11338736